Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
- PMID: 32401368
- PMCID: PMC7272857
- DOI: 10.1002/jmv.26004
Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
Conflict of interest statement
All the authors declare that there are no conflict of interests.
Comment on
-
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.J Med Virol. 2020 Jul;92(7):776-785. doi: 10.1002/jmv.25898. Epub 2020 May 3. J Med Virol. 2020. PMID: 32297988 Free PMC article.
References
-
- Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID‐19 infection [published online ahead of print March 30, 2020]. Med Mal Infect. 2020. 10.1016/j.medmal.2020.03.006 - DOI - PMC - PubMed
-
- Chorin E, Matthew D, Shulman E. The QT interval in patients with SARS‐CoV‐2 infection treated with hydroxychloroquine/azithromycin [published online ahead of print April 03, 2020]. medrxiv. 10.1101/2020.04.02.20047050 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical